Smith & Nephew share price reaches artificial high
This article was originally published in Clinica
Smith & Nephew will have to live with a grossly inflated figure as its year-high for the next 12 months after apparent extreme volatility in its share price over a two-day period. The price distortion was attributed to a new closing auction system operated by the London Stock Exchange, combined with a single transaction.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.